Table 1.

Evolution of the indications for FDA-approved PARP inhibitors.

PARP inhibitor	Year of approval	Indication and expanded indication
Olaparib	2014	Treatment of patients with deleterious or suspected deleterious germline BRCA mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
	2017	Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
	2018	Treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.
Rucaparib	2016	Treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube or primary peritoneal cancer who have been treated with two or more chemotherapies.
	2018	Maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Niraparib	2017	Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Talazoparib	2018	Treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer.

Data were extracted from the FDA Hematology/Oncology (Cancer) Approvals & Safety Notifications (accession date 29^th May 2018)⁶⁵.